MIDD0301 – A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression

We report a 28-day repeat dose immunotoxicity evaluation of investigational drug MIDD0301, a novel oral asthma drug candidate that targets gamma amino butyric acid type A receptors (GABA(A)R) in the lung. The study design employed oral administration of mice twice daily throughout the study period w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Basic Clin Pharmacol Toxicol
Main Authors: Zahn, Nicolas M., Huber, Alec T., Mikulsky, Brandon Nicholas, Stepanski, Mae Elizabeth, Kehoe, Alexander Scott, Li, Guanguan, Schussman, Melissa, Rashid Roni, M. S., Kodali, Revathi, Cook, James M., Stafford, Douglas C., Steeber, Douglas A., Arnold, Leggy A.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6565495/
https://ncbi.nlm.nih.gov/pubmed/30694594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcpt.13206
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki